7-chloro-5-cycloheptyl-6-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyrimidine | 847983-14-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 7-chloro-5-cycloheptyl-6-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyrimidine
• CAS: 847983-14-6
• 化学式: C₁₉H₁₇ClF₃N₃
• 分子量: 379.812
• InChiKey: GZOLQXQVVAFQQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-cycloheptyl-6-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyrimidin-7-ol 在 三氯氧磷 作用下， 反应 6.0h， 生成 7-chloro-5-cycloheptyl-6-(2,4,6-trifluorophenyl)imidazo[1,2-a]pyrimidine
  参考文献：
  名称：

  6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents

  摘要：

  本发明涉及某些6-芳基-7-卤代咪唑[1,2-a]嘧啶或其药学上可接受的盐以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是抗癌剂，可通过促进微管聚合来治疗哺乳动物的癌症。本发明还涉及一种治疗或抑制哺乳动物中癌细胞的生长和相关疾病的方法，并进一步提供了一种用于治疗或预防表达多药耐药性（MDR）或因MDR而耐药的癌症肿瘤的方法，该方法包括向所述哺乳动物施用所述化合物或其药学上可接受的盐的有效量。

  公开号：

  US20050065167A1

文献信息

• 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents
  申请人：Wyeth Holdings Corporation

  公开号：US07285555B2

  公开（公告）日：2007-10-23

  This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.

  本发明涉及某些6-芳基-7-卤代咪唑[1,2-a]嘧啶或其药学上可接受的盐以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是用于通过促进微管聚合治疗哺乳动物癌症的抗癌剂。本发明还涉及一种治疗或抑制哺乳动物癌症肿瘤细胞和相关疾病的方法，并进一步提供一种用于治疗或预防表达多药耐药性（MDR）的癌症肿瘤或因MDR而耐药的哺乳动物的方法，该方法包括向该哺乳动物施用所述化合物或其药学上可接受的盐的有效量。
• 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES AS ANTICANCER AGENT
  申请人：Wyeth Holdings Corporation

  公开号：EP1684763A1

  公开（公告）日：2006-08-02
• US7285555B2
  申请人：——

  公开号：US7285555B2

  公开（公告）日：2007-10-23
• US7915266B2
  申请人：——

  公开号：US7915266B2

  公开（公告）日：2011-03-29
• [EN] 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES AS ANTICANCER AGENT<br/>[FR] 6-ARYL-7-HALO-IMIDAZO[1,2-A]PYRIMIDINES, AGENTS ANTICANCEREUX
  申请人：WYETH CORP

  公开号：WO2005030218A1

  公开（公告）日：2005-04-07

  This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.